Risk Clinical Trials in Chicago, Illinois
17 recruitingChicago, Illinois
Showing 1–17 of 17 trials
Recruiting
Phase 3
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
High-risk Muscle Invasive Urothelial Carcinoma
AstraZeneca915 enrolled160 locationsNCT07720284
Recruiting
Phase 3
PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis
Coronary Artery Disease ProgressionPremature AtherosclerosisCoronary Artery Disease Risk Factors Multiple+1 more
Duke University1,500 enrolled23 locationsNCT07232069
Recruiting
Not Applicable
ELEVATE High-Risk PCI Pivotal Study
High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Magenta Medical Ltd.290 enrolled33 locationsNCT07001332
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled995 locationsNCT07181109
Recruiting
Not Applicable
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
Coronary Artery DiseaseInterventional CardiologyMechanical Circulatory Support+1 more
Supira Medical358 enrolled19 locationsNCT07296744
Recruiting
Phase 2
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
Breast Cancer InvasiveHigh Risk Breast CarcinomaEarly Stage Breast Cancer
University of Illinois at Chicago40 enrolled1 locationNCT04891068
Recruiting
Phase 2
Horizon Two: HR NDMM (MMRC-100)
High Risk Newly Diagnosed Multiple Myeloma
Multiple Myeloma Research Consortium300 enrolled7 locationsNCT07053436
Recruiting
Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant
Cirrhosis, LiverDiabetes Mellitus RiskTransplant-Related Disorder+1 more
University of Chicago60 enrolled1 locationNCT06950788
Recruiting
Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer
Colorectal, CancerEarly-onset Colorectal CancerDiet Habit+1 more
San Raffaele University2,300 enrolled8 locationsNCT05732623
Recruiting
Not Applicable
Moon and Sun Brothers: A Community Prevention Intervention (Hermanos de Luna y Sol)
Help-Seeking BehaviorCondomless SexRisky Health Behavior+1 more
San Francisco State University360 enrolled2 locationsNCT07475702
Recruiting
Phase 1
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Chronic Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia (CMML)+1 more
Crossbow Therapeutics, Inc.72 enrolled11 locationsNCT06994676
Recruiting
Phase 3
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
High-risk Large B-cell Lymphoma (LBCL)
Kite, A Gilead Company300 enrolled90 locationsNCT05605899
Recruiting
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Primary myelofibrosis (PMF)Myeloproliferative DisordersMyelofibrosis+49 more
MPN Research Foundation5,000 enrolled2 locationsNCT07362225
Recruiting
Not Applicable
Mirai-MRI: Validation of AI Models for Breast Cancer Risk
Cancer RiskBreast Cancer Risk
University of California, San Francisco400 enrolled4 locationsNCT07121972
Recruiting
Not Applicable
Optimizing the Floreciendo Sexual and Reproductive Health Workshop for Latina Teens and Female Caregivers: A Pilot
Unplanned pregnancySexually Transmitted InfectionsSexual Risk Behavior
University of Illinois at Chicago184 enrolled4 locationsNCT06223165
Recruiting
Phase 2
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Prostate CancerProstate CancersProstate Cancer (Adenocarcinoma)+4 more
Cellvax Therapeutics Inc100 enrolled3 locationsNCT06636682
Recruiting
Phase 1
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
SarcomaSCLCMalignant Melanoma+1 more
Y-mAbs Therapeutics60 enrolled8 locationsNCT05130255